KM Pharmaceutical, a South Korean OEM/ODM specialist in oral care and lifestyle beauty, has signed a non-binding MOU with a US strategic partner to expand its presence in the North American market. The agreement targets four key areas: distribution of KM's own brands, OEM/ODM production for the partner's new brands, private-label OEM supply for major US retailers, and entry into high-barrier channels including military and B2B networks. This move signals growing opportunities for overseas buyers seeking reliable Korean manufacturing partners with established channel access in the US.
Four-pronged cooperation framework
The MOU, signed during CEO Baek Seung-won's business trip to the US, outlines four main areas of collaboration. First, KM will accelerate US distribution of its own brands, including hair care line ZEROCIPE (featuring nanographene) and oral care brand FOAMGLE. Second, the partner will contract KM for OEM/ODM production of new foam-formula oral care, skincare, and health functional food brands for the US market.
Targeting high-barrier US channels
A key focus is joint pursuit of OEM supply opportunities with major US retailers' private-label programs. The companies also plan to supply KM-manufactured foam oral care products to US military distribution channels and B2B supply chains. KM's proprietary foam-formulation technology and mass-production experience position it as a stable manufacturing partner for these demanding segments.
Strategic rationale and partner profile
The US partner is a specialized firm with years of experience in government and institutional procurement channels, offering access to B2B and institutional distribution networks that are typically difficult for consumer goods companies to penetrate alone. The partner's name will be disclosed upon final contract signing. CEO Baek stated: "The next challenge for K-beauty in North America is not new entry but channel diversification—expanding beyond general retail into high-barrier channels like military and B2B is true market capture."
What buyers should watch
For overseas importers and distributors, this MOU highlights KM Pharmaceutical's capability to serve as a turnkey OEM/ODM partner for foam-formula oral care and skincare products destined for US institutional and retail channels. The company's existing technology and mass-production experience, combined with a partner that holds government procurement relationships, could offer a streamlined route for buyers seeking to launch private-label or branded products in the US market. However, the non-binding nature of the MOU means final terms and timelines remain subject to negotiation.
Sourcing context
KM Pharmaceutical is a publicly listed company in South Korea specializing in oral care and lifestyle beauty OEM/ODM. Its portfolio includes foam-formula oral care products, nanographene-based hair care, and health functional foods. The company has previously collaborated with Hanul Bio on MPC-material mouthwash development and renewed its Pororo toothpaste line for global markets.
Source: Read the original report | Published: June 01, 2026